We showed that GCNT3 expression increases in High-grade IPMN (Fig. 2d) and is conserved in PDAC and metastasis (Additional file 1: Figure S1) where it defines a population with an adverse prognosis (122 patients out of 177, TCGA data) (Fig. 2c), entailing its eligibility as target for a novel therapy. This evidence concerns the gene GCNT3 and pancreatic intraductal papillary-mucinous neoplasm.